Qezzaqar
Application withdrawn
catequentinib
MedicineHumanApplication withdrawn
Italian is available via eTranslation, the European Commission's machine translation service.
Translate to Italian | Important information about machine translation
CATS Consultants GmbH withdrew its application for a marketing authorisation of Qezzaqar for the treatment of leiomyosarcoma and synovial sarcoma, two types of cancer of the soft tissue.
The company withdrew the application on 30 October 2026.
Qezzaqar was developed as a cancer medicine for the treatment of two types of soft tissue sarcoma (a type of cancer that affects the soft, supportive tissues of the body):
Qezzaqar contains the active substance catequentinib and was to be available as capsules to be taken by mouth.
Qezzaqar was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 February 2018 for the treatment of soft tissue sarcoma.
The active substance in Qezzaqar, catequentinib, belongs to a class of cancer medicines called tyrosine kinase inhibitors and blocks several receptors (targets) that help the cancer to grow, including VEGF receptors. By blocking these receptors, the medicine was expected to slow the cancer’s growth and spread.
The company presented data from a main study which involved patients with different types of cancer. Of these patients, 79 had metastatic or advanced synovial sarcoma and received either Qezzaqar or dacarbazine, a chemotherapy treatment, while 111 patients had metastatic or advanced leiomyosarcoma and received either Qezzaqar or placebo (a dummy treatment). In both groups, the main measure of effectiveness was how long patients lived without their disease getting worse (progression-free survival).
The evaluation had finished and the European Medicines Agency had recommended refusing marketing authorisation. The company had requested a re-examination of the Agency’s recommendation, but it withdrew the application before this re-examination had finished.
Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had recommended refusing marketing authorisation for Qezzaqar for the treatment of leiomyosarcoma and synovial sarcoma.
The Agency concluded that, in both conditions, the benefits observed in terms of progression-free survival were very limited and not supported by other measures of effectiveness such as objective responses to treatment (shrinkage of the tumour or no detectable sign of cancer after treatment) or overall survival (how long people lived overall). In addition, there were significant uncertainties about the robustness of the data. In particular, due to the small size of the control groups (patients given placebo or a comparator medicine), differences between participants at the start of the study may have had an impact on the results. In terms of safety, in line with other VEGF inhibitors, Qezzaqar is associated with important side effects, including some that were serious and led to death.
In its letter notifying the Agency of the withdrawal, the company stated that its decision was based on feedback from EMA’s scientific advisory group on oncology (which was consulted during the re-examination) and human medicines committee (CHMP) which indicated that the Agency would not be able to conclude that the benefits outweigh the risks.
The company informed the Agency that there are no consequences for patients in clinical trials or in compassionate use programmes with Qezzaqar for these two indications.
If you are in a clinical trial or compassionate use programme and need more information about your treatment, speak with your clinical trial doctor.
Orphan
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.